Antibacterial Agents TRIZ Cases

An intradermal PCV2 vaccine using recombinant ORF2 protein extends immunity to 23 weeks while reducing systemic side effects.

Chimeric molecules merge costimulatory ligands and epitopes to overcome T cell tolerance and reduce liver stage parasite burden.

Local pulmonary administration of fosfomycin treats bacterial lung infections while avoiding systemic organ toxicity and antibiotic resistance.

N-alkyl 2-disubstituted alkynyladenosine-5'-uronamides provide selective A2A receptor agonism to reduce side effects from wide receptor distribution.

Boric acid and EDTA vaginal suppositories disrupt pathogenic biofilms, addressing resistance to conventional antimicrobial therapies.

Non-lipidated bacterial outer-membrane polypeptides induce robust cellular immune responses through targeted cytokine production and T cell activation.

Lipid-modified defensin octapeptides eradicate drug-resistant biofilms while preserving natural microbiota diversity.

Spray-dried liposomes encapsulate hydrophobic CoQ10 to bypass mechanical degradation and ensure stable deep lung deposition.

Solid non-porous polymer composites maintain constant therapeutic drug concentrations by eliminating first-order release decay.

Merging CD27 agonists with PD-1 or CTLA-4 inhibitors overcomes immune tolerance to enhance antigen-specific T-cell activation.

Flexible elongate body with bladder-end drug reservoir uses osmotic pressure to pump medication through ureter.

fHbp antigen combined with aluminium salt adjuvant induces protective immune response against serogroup X meningococcus without complex outer membrane vesicles.

Liposome encapsulation delivers pneumococcal capsular polysaccharide antigens without carrier proteins, eliminating asthma induction risk and production costs.

N-terminal truncation of APG101 fusion proteins enhances stability while maintaining production yield.

Composite hyaluronic acid hydrogel prevents implant infection by maintaining effective drug concentrations for up to 72 hours.

Human monoclonal antibodies target enterococci to overcome antibiotic resistance through universal binding.

Nucleic acid aptamers replace antibodies to inhibit C3 activation, eliminating protein aggregation and reducing production costs.

Genetically engineered microorganisms target diseased epithelial cells to secrete detectable biomarkers into body fluids.

Modified chaperonin 10 polypeptides retain immunomodulatory activity while lacking protein folding function.

Specific MTAN inhibitors overcome antibiotic resistance in peptic ulcers by targeting bacterial enzyme activity.

Lipoic acid conjugates with aromatic rings treat infections caused by multi-drug resistant and persister bacteria.

Monoclonal antibodies targeting lipopolysaccharides and flagellin reduce bacterial loads in multidrug-resistant Pseudomonas aeruginosa infections.

Brevibacterium casei AP9 resolves poor pH tolerance in conventional probiotics by delivering superior digestive survival and cholesterol reduction.